История изменений

Detection of antibodies

Part of the immune response to infection is the production of antibodies including IgM and IgG. These can be used to detect infection in individuals starting 7 days or so after the onset of symptoms, to determine immunity, and in population surveillance.[citation needed]

Assays can be performed in central laboratories (CLT) or by point-of-care testing (PoCT). The high-throughput automated systems in many clinical laboratories will be able to perform these assays but their availability will depend on the rate of production for each system. For CLT a single specimen of peripheral blood is commonly used, although serial specimens can be used to follow the immune response. For PoCT a single specimen of blood is usually obtained by skin puncture. Unlike PCR methods an extraction step is not needed before assay.[citation needed]

It was hoped that a point of care test will be available in the United States by 30 March.[30]

A blood test to detect antibodies is being developed as of 9 March 2020.[31] It will allow the determination of whether a person has ever been infected and will work regardless of whether the person developed symptoms.[31] It is hoped that it can return results in 15 minutes by detecting both IgM and IgG antibodies.[32]

In late March 2020, Euroimmun Medical Laboratory Diagnostics and Epitope Diagnostics received European approvals for their test kits, which can detect IgG and IgA antibodies against the virus in blood samples. The testing capacity is several hundred samples within hours and therefore much faster than the conventional PCR assay of viral RNA. The antibodies are usually detectable 14 days after the onset of the infection.[33] 

Detection of antibodies

Part of the immune response to infection is the production of antibodies including IgM and IgG. These can be used to detect infection in individuals starting 7 days or so after the onset of symptoms, to determine immunity, and in population surveillance.[citation needed]

Assays can be performed in central laboratories (CLT) or by point-of-care testing (PoCT). The high-throughput automated systems in many clinical laboratories will be able to perform these assays but their availability will depend on the rate of production for each system. For CLT a single specimen of peripheral blood is commonly used, although serial specimens can be used to follow the immune response. For PoCT a single specimen of blood is usually obtained by skin puncture. Unlike PCR methods an extraction step is not needed before assay.[citation needed]

It was hoped that a point of care test will be available in the United States by 30 March.[30]

A blood test to detect antibodies is being developed as of 9 March 2020.[31] It will allow the determination of whether a person has ever been infected and will work regardless of whether the person developed symptoms.[31] It is hoped that it can return results in 15 minutes by detecting both IgM and IgG antibodies.[32]

In late March 2020, Euroimmun Medical Laboratory Diagnostics and Epitope Diagnostics received European approvals for their test kits, which can detect IgG and IgA antibodies against the virus in blood samples. The testing capacity is several hundred samples within hours and therefore much faster than the conventional PCR assay of viral RNA. The antibodies are usually detectable 14 days after the onset of the infection.[33] 

Detection of antibodies

Part of the immune response to infection is the production of antibodies including IgM and IgG. These can be used to detect infection in individuals starting 7 days or so after the onset of symptoms, to determine immunity, and in population surveillance.[citation needed]

Assays can be performed in central laboratories (CLT) or by point-of-care testing (PoCT). The high-throughput automated systems in many clinical laboratories will be able to perform these assays but their availability will depend on the rate of production for each system. For CLT a single specimen of peripheral blood is commonly used, although serial specimens can be used to follow the immune response. For PoCT a single specimen of blood is usually obtained by skin puncture. Unlike PCR methods an extraction step is not needed before assay.[citation needed]

It was hoped that a point of care test will be available in the United States by 30 March.[30]

A blood test to detect antibodies is being developed as of 9 March 2020.[31] It will allow the determination of whether a person has ever been infected and will work regardless of whether the person developed symptoms.[31] It is hoped that it can return results in 15 minutes by detecting both IgM and IgG antibodies.[32]

In late March 2020, Euroimmun Medical Laboratory Diagnostics and Epitope Diagnostics received European approvals for their test kits, which can detect IgG and IgA antibodies against the virus in blood samples. The testing capacity is several hundred samples within hours and therefore much faster than the conventional PCR assay of viral RNA. The antibodies are usually detectable 14 days after the onset of the infection.[33]